Immunovaccine
About Us
Overview
Leadership
Board of Directors
Scientific and Clinical Advisory Committee
Company History
Business Development
Partnerships
Careers
Overview
Openings
Life at IMV
Clinical Trials
Overview
Ongoing Trials
DPX-Survivac
Platform
Overview
Other Applications
Intellectual Property
Publications
Research and Development
Overview
Immuno-oncology
Investors
Overview
Press Releases
Events, Webcasts & Presentations
Financial Info
Stock Data
Filings
Governance
Contact Us
FAQ
Newsroom
Latest News
Archives
Media Contact
Contact Us
Clinical Trials
- Overview
- Ongoing Trials
-- Expanded Access
-- Investigator-initiated Trials
- DPX-Survivac
Research and Development
- Overview
- Immuno-oncology
-- Ovarian Cancer
Platform
- Overview
- Other Applications
-- Infectious Diseases
- Intellectual Property
- Publications
About Us
- Overview
- Leadership
- Board of Directors
- SCAC
- Company History
- Business Development
- Partnerships
Investors
- Stock Information
- Press Releases
- Analyst Coverage
- Events, Webcasts, Presentations
- Financial Information
- Tax Information
- Proxy Information
- SEC Filings
- SEDAR Regulatory Filings
- Corp Governance
- Investor FAQs
- Contact Us
Newsroom
- Overview
- Archives
- Media Contact
Contact Us
Careers
- Overview
- Openings
- Life at Immunovaccine
- Life in Halifax
All SEC Filings
Investors
Investors
Overview
Press Releases
Events, Webcasts & Presentations
Overview
Presentations
Scientific Posters
Email Alerts
Financial Info
Financial Results
Tax Info
Proxy Info
Stock Option Plan
Deferred Share Unit Plan
Stock Data
NASDAQ: IMV
TSX: IMV
Analyst Coverage
Filings
All SEC Filings
Annual Reports
SEDAR
Governance
Overview
Board of Directors
Board Committees
Governance Documents
Contact Us
FAQ
Filings
All SEC Filings
Annual Reports
SEDAR
Filing Type:
View All
40-F
40FR12B
40FR12B/A
6-K
CERT
D
EFFECT
F-10
F-10/A
F-X
F-X/A
S-8
SC 13D
SC 13G
SC 13G/A
SUPPL
Year:
View All
2020
2019
2018
Date
Form
Description
PDF
XBRL
Pages
06/15/20
6-K
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
Documents
EX-99.1
7
06/08/20
6-K
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
Documents
EX-99.1
5
06/03/20
6-K
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
Documents
EX-99.1
EX-99.2
EX-99.3
EX-99.4
57
05/29/20
6-K
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
Documents
EX-99.1
7
05/27/20
S-8
Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Documents
EX-4.1
EX-5.1
EX-23.2
21
05/21/20
6-K
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
Documents
EX-99.1
7
05/18/20
D
Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(a)(5) under the Act.
6
05/15/20
6-K
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
Documents
EX-99.1
10
05/15/20
6-K
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
Documents
EX-99.1
EX-99.2
EX-99.3
EX-99.4
49
05/12/20
6-K
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
Documents
EX-99.1
5
1
2
3
4
5
6
7
8
9
10
…13
Next
Email Alerts
Contacts
RSS News Feed